CDMRP: Pancreatic Cancer Research Program (PCARP)

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

The FY26 Pancreatic Cancer Research Program (PCARP) is anticipated to issue multiple funding opportunities to accelerate impactful research in pancreatic cancer, spanning early detection, supportive care, risk characterization, access to care, metabolic dysregulation, tumor development, biomarkers, and new therapeutics. Investigators should begin planning now—formal Funding Opportunity Announcements (FOAs), deadlines, and application requirements will be posted on Grants.gov once released. This pre-announcement does not obligate funding but signals that awards will be available in FY26.

How much funding would I receive?

Funding varies by mechanism:

• Focused Pilot Award: Up to $300,000 total costs over up to 2 years.

• Idea Development Award: Up to $700,000 total costs over up to 3 years (standard) or $950,000 total costs with Partnering PI Option.

• Translational Research Partnership Award: Up to $1.1 million total costs over up to 3 years.

What could I use the funding for?

Funding supports research that directly addresses one or more of the following PCARP Focus Areas:

Scientific & Clinical Focus Areas

• Early detection research

• Identification and characterization of risk

• Supportive care, quality of life, and patient perspectives

• Healthcare access barriers and care delivery challenges

• Metabolic disruptions (including diabetes, cachexia)

• Tumor development from precursor lesions to metastasis

• Biomarkers for response prediction and management strategies

• Novel therapeutic targets and approaches

Each award mechanism may have specific constraints on what types of work it can support (e.g., some do not fund clinical trials or basic research).

Are there any additional benefits I would receive?

• Early insight into programmatic priorities via this pre-announcement.

• Access to eBRAP system for managing pre-applications.

• Email subscription updates when official FOAs are released.

What is the timeline to apply and when would I receive funding?

• Pre-announcement published: February 12, 2026.

• Official FOAs: To be posted on Grants.gov (dates not yet announced).

• Submission Deadlines: Will be specified in each FOA (pre-application and full application deadlines).

• Funding Start: Following review, award negotiation, and execution (typical CDMRP cycle timing, exact months TBD).

Where does this funding come from?

PCARP is funded through the FY26 Defense Appropriations Act and managed within the Defense Health Agency Research and Development – Medical Research and Development Command (DHA R&D-MRDC) as part of the Congressionally Directed Medical Research Programs (CDMRP).

Who is eligible to apply?

Eligibility depends on the award mechanism:

• Focused Pilot Award: Investigators at any career level, including postdoctoral and clinical fellows.

• Idea Development Award: Independent investigators at any career stage; early-career investigators may partner with experienced PIs.

• Translational Research Partnership Award: Independent investigators; postdoctoral/clinical fellows are not eligible.

What companies and projects are likely to win?

Projects most competitive for PCARP will:

• Directly address one or more specified focus areas with strong scientific rationale.

• Demonstrate innovation and potential impact on pancreatic cancer outcomes.

• Align with mechanism goals (e.g., pilot studies for early-stage ideas, partnerships for translational work).

• Include appropriate preliminary data when required.

Are there any restrictions I should know about?

• Focused Pilot Award: No basic research, pre-clinical animal studies, or clinical trials.

• Idea Development & Translational Awards: Clinical trials and some animal work may be restricted or defined in FOA; check carefully.

• Pre-proposal or letter of intent submission is required prior to full application for many mechanisms.

How long will it take me to prepare an application?

Time depends on mechanism and data readiness:

• Focused Pilot Award: Plan ~4–8 weeks for a competitive pre-application and research plan.

• Idea Development & Translational Awards: With required preliminary data, plan ~8–16+ weeks to assemble data, collaborators, and a strong proposal.

Start early given the expected complexity of CDMRP applications.

How can BW&CO help?

BW&CO can help you:

• Interpret future FOA requirements and priorities.

• Structure pre-applications/letters of intent for maximum impact.

• Craft narrative, budget justification, and compliance sections.

• Align scientific aims with program focus areas to increase competitiveness.

How much would BW&CO Charge?

We have both fractional engagements ($250 an hour) and full engagements ($13,000 + 5%) available.

Additional Resources

Review the solicitation here.

CDMRP: Lupus Research Program (LRP)

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

The CDMRP’s FY26 Lupus Research Program (LRP) pre-announcement signals anticipated funding opportunities supporting innovative, high-impact lupus research aimed at understanding, preventing, diagnosing, and treating lupus, as well as improving the quality of life for individuals living with lupus. This pre-announcement does not include application deadlines or guarantee funding — the official Funding Opportunity Announcements (FOAs) will be posted on Grants.gov with formal deadlines and requirements. Investigators should begin planning now to align with expected FY26 mechanisms and program goals.

How much funding would I receive?

The pre-announcement outlines multiple award mechanisms with specified maximum total costs:

• Idea Award – up to $300,000 (2 years)

• Impact Award – up to $1,000,000 (4 years)

• Transformative Vision Development Award – up to $250,000 (2 years)

• Transformative Vision Award – up to $2,000,000 (4 years)

What could I use the funding for?

Funding must support research aligned with one or more LRP focus areas:

Biological & Clinical Research

• Mechanisms of lupus disease and pathobiology

• Genetic, epigenetic, and gene–environment interaction studies

• Disease heterogeneity, presentations, and outcomes
  Applies to Idea & Impact Awards

Quality of Life & Intervention Studies

• Addressing social determinants of health

• Nutrition, symptom control, comparative effectiveness

• Outcomes research and patient-reported outcomes
  Applies to Impact, Transformative Vision Development, and Transformative Vision Awards

Innovative Health Care Delivery Models

• Models improving lupus outcomes
  Applies to Impact, Transformative Vision Development, and Transformative Vision Awards

Are there any additional benefits I would receive?

• Mechanism clarity ahead of FOAs allows early planning.

• Subscribe to email updates through eBRAP for timely notifications when FOAs are released.

• Being positioned early can improve competitiveness.

What is the timeline to apply and when would I receive funding?

• Pre-announcement released: February 11, 2026.

• Formal FOAs — will be posted on Grants.gov with official pre-application and full application deadlines.

• Investigators must submit a pre-application through eBRAP prior to the pre-application deadline specified in the FOAs.

Where does this funding come from?

Funding is provided through the FY26 Defense Appropriations Act appropriated to the Congressionally Directed Medical Research Programs (CDMRP) and managed by the Defense Health Agency Research & Development and Medical Research and Development Command (DHA R&D-MRDC).

Who is eligible to apply?

Eligibility is defined by mechanism:

• Idea Award: Investigators at or above postdoctoral level.

• Impact & Transformative Awards: Investigators at or above Assistant Professor (or equivalent).

• Team Requirements: Transformative mechanisms must include at least one lupus consumer advocate as part of the research team.

What companies and projects are likely to win?

Projects that:

• Align tightly with the specified focus areas.

• Demonstrate high innovation and impact potential.

• Involve strong preliminary data (as required for Transformative Vision Award).

• Include meaningful involvement of lupus consumer advocates (for transformative mechanisms).

Are there any restrictions I should know about?

• This pre-announcement is not a funding commitment; only the FOAs establish requirements and obligations.

• Applications cannot support clinical trials in Idea or Impact Awards; Transformative Vision Awards may support clinical trials but not animal studies.

• Transformative Vision Development Awards cannot support clinical trials or animal studies.

How long will it take me to prepare an application?

Preparation time depends on mechanism and complexity, but begin planning now — especially for pilot data and consumer engagement for transformative mechanisms. Historically, competitive CDMRP applications often require several weeks to months of focused preparation.

How can BW&CO help?

BW&CO can:

• Develop alignment narratives tied to LRP focus areas.

• Assist with preliminary data framing and research strategy articulation.

• Craft strong consumer advocacy integration plans.

• Ensure conformity with CDMRP review criteria once FOAs are released.

How much would BW&CO Charge?

We have both fractional engagements ($250 an hour) and full engagements ($13,000 + 5%) available.

Additional Resources

Review the solicitation here.

CDMRP: Breast Cancer Research Program (BCRP)

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

The Breast Cancer Research Program (BCRP), managed by the Congressionally Directed Medical Research Programs (CDMRP), has released a Pre-Announcement for anticipated Fiscal Year 2026 (FY26) funding opportunities to support innovative, high-impact research aimed at ending breast cancer for Service Members, Veterans, their families, and the general public. This pre-announcement is intended to let investigators plan and develop proposals before the full Funding Opportunity Announcements (FOAs) are posted on Grants.gov. The government does not guarantee awards based on this document alone. FOA release dates, pre-application, and application deadlines will be announced on Grants.gov and eBRAP. Driven investigators should begin conceptualizing competitive approaches immediately.

How much funding would I receive?

The Pre-Announcement outlines anticipated award types with specified maximum total costs for FY26:

Breakthrough Award

• Level 1: up to $750,000 (single PI) or $1.25M (partnering PIs)

• Level 2: up to $1.65M (single PI) or $2.5M (partnering PIs)

• Population Science (Level 2): up to $2.5M (single) or $3.35M (partnering)

• Level 3: up to $5.6M (single) or $7M (partnering)

• Level 4: up to $21M
  (Breakthrough Awards range from early high-risk ideas to transformative approaches.)

Other Anticipated Mechanisms

• Era of Hope Scholar Award: up to $4.9M

• Clinical Research Extension Award: up to $7M (single) / $8.4M (partnering)

• Transformative Breast Cancer Consortium Award: up to $35M

• Transformative Breast Cancer Consortium Development Award: up to $140,000
  (These awards support early-career investigators, ongoing clinical research, and large multi-project consortia.)

What could I use the funding for?

Funded research must address one or more overarching challenges critical to ending breast cancer:

Topic Areas / Research Aims

• Primary prevention of breast cancer

• Determinants of initiation, risk, or susceptibility

• Distinguishing lethal vs. non-lethal tumors

• Solutions to overdiagnosis/overtreatment

• Pathways driving tumor growth and metastasis

• Mechanisms of dormancy and lethal recurrence

• More effective, less toxic treatments

• Reducing mortality from metastatic disease

Mechanism-Specific Uses

• Breakthrough Awards: high-risk/high-reward or translation-focused research

• Era of Hope Scholar Award: early-career leadership and innovation

• Clinical Research Extension: extending clinical data collection and analysis

• Consortium Awards: integrated multi-project collaborations toward transformative goals

(Mechanism scopes will be confirmed in the FOAs.)

Are there any additional benefits I would receive?

Participating teams may benefit from:

• Collaborative frameworks with consumer advocates required on some mechanisms

• Access to eBRAP support and templates for submission guidance

What is the timeline to apply and when would I receive funding?

• Pre-Announcement Released: February 2026 (no exact FOA deadlines yet)

• FOAs and deadlines: Will be posted on Grants.gov and eBRAP once finalized.

• Plan: Prepare project concepts now; watch Grants.gov and eBRAP for pre-application and application due dates, which may be weeks to months after FOA publication. Award start dates typically follow after review and appropriation obligations.

Where does this funding come from?

This funding is provided by the FY26 Defense Appropriations Act under the Department of Defense’s Congressionally Directed Medical Research Programs, specifically appropriated for breast cancer research.

Who is eligible to apply?

Eligibility varies by mechanism but generally includes:

• Investigators at all academic levels or equivalent (Breakthrough, Clinical Extension)

• Independent investigators (higher level awards)

• Teams including consumer advocates for specified awards

• Exact eligibility will be detailed in each FOA.

(Final eligibility criteria are determined in the FOAs.)

What companies and projects are likely to win?

Competitive proposals typically:

• Address key overarching challenges defined by BCRP

• Demonstrate innovation, clinical relevance, and impact

• Include translational pathways or transformative potential

• Meet mechanism-specific expectations (e.g., data access plans, interdisciplinary teams)

Are there any restrictions I should know about?

• This pre-announcement is not a FOA and does not guarantee funding.

• Final applications must conform to Grants.gov FOAs once released.

• Mechanism specific limits on clinical trials and preliminary data requirements will be in each FOA.

How long will it take me to prepare an application?

Preparation time varies by project complexity, but given the breadth of mechanisms and expected competitive standards, begin planning now while awaiting FOAs:

• Concept refinement: ~2–4 weeks

• Team assembly & consumer advocate engagement: ~2–6 weeks

• Budget & prelim data planning: ~4–8+ weeks depending on scope

How can BW&CO help?

BW&CO can assist with:

• Translating BCRP FOA language into tailored project responses

• Drafting narrative, budget justification, and impact sections

• Aligning your concept with mechanism-specific review criteria

• Incorporating consumer review perspectives where required

How much would BW&CO Charge?

We have both fractional engagements ($250 an hour) and full engagements ($13,000 + 5%) available.

Additional Resources

Review the solicitation here.

Administration for Community Living (ACL): Caregiver AI Challenge

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

The Caregiver AI Challenge is a new federal prize competition launched by the Administration for Community Living (ACL), part of the U.S. Department of Health and Human Services (HHS), to accelerate practical, ethical, and scalable AI technologies that support caregivers—including family, friends, and direct care workers—across the U.S. Caregiving demands are rising dramatically, and this challenge seeks tools that reduce caregiver burden, improve quality of care, and strengthen workforce systems. Phase 1 of the competition is open for applications now, with a Phase 1 deadline of July 31, 2026 for submissions.

How much funding would I receive?

• Total Phase 1 funding pool: up to $2.5 million across prizes for winners.

• Phase 1 prizes: Up to 10 awards of up to $100,000 each per track.

• Additional merit prizes up to $50,000 for targeted focus areas (e.g., dementia support, interoperability, partnerships).

• Subsequent phases will have additional prizes (to be announced).

What could I use the funding for?

Caregiver Support Tools (Track 1)

• AI technologies that assist home caregivers with daily tasks.

• Tools that improve scheduling, monitoring, communication, safety, documentation reduction, or training support.

Workforce Support Tools (Track 2)

• AI solutions that help home care employers and networks improve efficiency, task automation, staff scheduling, recruitment/retention, and training systems.

Are there any additional benefits I would receive?

• Public recognition and validation of your technology within federal aging/disability networks.

• Technical assistance and access to federal and non-federal partners during phases.

• Potential momentum toward commercialization, scaling, and follow-on opportunities.

What is the timeline to apply and when would I receive funding?

• Phase 1 application deadline: July 31, 2026 (established in press coverage).

• Winners for Phase 1 are selected after the application review following that deadline.

• Funding is typically paid out after phase awards are announced and eligibility requirements are met.

Where does this funding come from?

This is a federal prize competition administered by the ACL within HHS and conducted under the America COMPETES Act, aimed at catalyzing innovation in caregiving through responsible AI technologies.

Who is eligible to apply?

Individuals, teams, or organizations of any type may apply as long as they comply with competition eligibility.

1. Applicants must be 18 or older.

2. U.S. citizens/permanent residents are eligible to win prizes; non-U.S. participants can participate but cannot receive prize awards.

What companies and projects are likely to win?

Likely winners will propose AI solutions that:

• Are already at Technology Readiness Level (TRL) ≥ 3 with concrete design and use cases.

• Demonstrate strong human-centered design with caregiver input.

• Show potential to improve caregiving safety, reduce burden, or extend workforce capabilities.

• Align with responsible AI principles (privacy, accountability, transparency, safety).

Are there any restrictions I should know about?

• Federal employees/involved parties and federal entities cannot win.

• Solutions must directly address caregiver challenges (not tangential AI tech).

• Must respect competition responsible AI design principles (e.g., privacy, dignity, user control).

How long will it take me to prepare an application?

Preparation time will vary based on the maturity of your AI tool; typical steps include:

• Defining caregiver problems and solution design (expert interviews).

• Documenting technology readiness and evidence of impact.

• Drafting implementation/testing plans that integrate caregiver/user feedback.
  Expect several weeks to months of preparation for a competitive submission.

How can BW&CO help?

BW&CO can:

• Translate the competition’s priorities into compelling narrative Q&A (aligned with HHS goals).

• Map your technology’s current progress to the Phase 1 judging criteria.

• Assist with application drafting to emphasize caregiver impact and responsible AI design.

How much would BW&CO Charge?

We have both fractional engagements ($250 an hour) and full engagements ($13,000 + 5%) available.

Additional Resources

Review the solicitation here.

DIU: Runway Independent Maritime & Expeditionary Strike (RIMES)

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

This is a DIU Commercial Solutions Opening (CSO) that invites companies with novel unmanned aerial systems (UAS) capable of providing long-range strike support for naval surface combatants—without relying on large runways or flight decks—to submit a solution. It is a fast, flexible path to a prototype Other Transaction (OT) award that could potentially lead to follow-on production contracts across the U.S. Department of Defense. Proposals are due February 27, 2026 at 23:59:59 US/Eastern Time.

How much funding would I receive?

The DIU CSO does not specify a fixed award amount on the posting. Instead, selected vendors typically negotiate a prototype Other Transaction (OT) agreement. Funding levels vary based on solution complexity and scope, and successful prototype awards can lead to larger follow-on production arrangements.

What could I use the funding for?

You may propose funding for:

• Technical development of a long-range UAS capability that meets the challenge criteria

• Prototyping of vehicle hardware, autonomy software, and integration with naval systems

• Test, evaluation, and demonstration efforts

• Integration and safety risk reduction activities

• Personnel, materials, subcontractors, and other direct costs aligned with system delivery and prototype execution

DIU’s focus is mission-relevant prototyping that can be transitioned rapidly to DoD users.

Are there any additional benefits I would receive?

If your prototype is successful:

• You may be considered for follow-on production contracts or agreements that do not require further competitive procedures, under 10 U.S.C. 4022(f).

• DIU’s CSO process provides strategic exposure and faster contracting than traditional DoD pathways.

What is the timeline to apply and when would I receive funding?

Submission Deadline: February 27, 2026 at 23:59:59 US/Eastern — submit solution brief by this time.

After submission:

• DIU reviews briefs and may invite you to pitch or submit a full proposal.

• Prototype OT awards are typically executed weeks to a few months after selection, depending on evaluations and negotiations.

Where does this funding come from?

This solicitation is run by the Defense Innovation Unit (DIU) — a Department of Defense organization that accelerates commercial technology adoption for national security missions. It uses Other Transaction Authority (OTA) to award prototype agreements directly to commercial tech companies.

Who is eligible to apply?

• U.S. and foreign owned businesses are generally eligible; eligibility specifics are governed by the broader CSO requirements.

• Companies must register in SAM.gov and obtain a CAGE code prior to award if not already registered.

• A CMMC Level 2 (Self) cybersecurity posture is required before award.

DIU encourages commercial entities of all sizes — including first-time defense contractors — to submit solutions.

What companies and projects are likely to win?

Strong candidates will offer a UAS that:

• Operates without runways or large flight decks

• Has ≥1400 NM one-way range with a ~1000-lb payload of standard naval munitions

• Integrates with existing combat systems

• Demonstrates mission autonomy and resilience in contested environments

• Offers cost-effective, maintainable, and scalable approaches

• Supports rapid prototyping and field demonstration within 12 months

Projects that show technical maturity, clear operational benefit, and transition readiness are most competitive.

Are there any restrictions I should know about?

• Solutions must meet DIU CSO format and content requirements, typically not exceeding five pages or fifteen slides.

• CMMC Level 2 (Self) compliance is required before award.

• Any award will include compliance with applicable laws such as Section 889 NDAA requirements.

How long will it take me to prepare an application?

• A compliant Solution Brief should take a few weeks of focused effort to develop, including company overview, technical description, risk assessment, and linkage to challenge attributes.

• For competitive positioning, start well before the deadline to refine mission relevance and prototype feasibility.

How can BW&CO help?

BW&CO can help you:
• Translate your technical capabilities into a competitive DIU solution brief.
• Strategize on Line of Effort selection and demo readiness.
• Prepare compliance documentation and security coordination plans.
• Draft a high-impact live demonstration plan that aligns with DIU and DoD expectations.

How much would BW&CO Charge?

We have an hourly rate to strategize, review, and edit applications of $250.

Additional Resources

Review the solicitation here.

DIU: Counter UAS Sensing for Homeland and Mobile Defense

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

The Defense Innovation Unit (DIU) seeks commercial sensing solutions to detect, track, and classify small unmanned aerial systems (sUAS) for fixed homeland defense and mobile tactical use. This Commercial Solutions Opening (CSO) is urgent due to evolving UAS threats, and responses are due by February 26, 2026 at 23:59:59 US Eastern Time. Selected companies may be invited to a Phase 2 live demonstration at Yuma Proving Ground (AZ) in Spring 2026 — at the company’s expense — making quick readiness and regulatory compliance essential.

How much funding would I receive?

DIU does not list a specific award amount on the submission page. As a CSO, funding typically depends on the solution’s relevance and negotiation between DIU, the DoD sponsor, and the vendor — often structured as an Other Transaction (OT) prototyping agreement. Follow-on production awards can be significantly larger if the prototype is successful.

What could I use the funding for?

Prototypes should deliver scalable, survivable, life-saving sUAS sensing capabilities in two categories:
• Line of Effort 1 — Homeland Defense Sensing:

• Persistent fixed-site sensing near population centers and congested airspace.

• Must include a radar sensor with high-performance detection, tracking, and classification.
  • Line of Effort 2 — Mobile Tactical Sensing:

• Resilient, low-signature systems that operate stationary and on-the-move in GNSS-denied or contested environments.
  Proposals must demonstrate technical performance, integration paths, and operational readiness.

Are there any additional benefits I would receive?

• Rapid engagement with the U.S. Department of Defense through DIU’s CSO process.
• Potential transition to follow-on production contracts without further competition if your prototype meets success criteria under 10 U.S.C. 4022(f) authority.
• Exposure to DoD partners and Program Managers at demonstration events (e.g., Yuma Proving Ground).

What is the timeline to apply and when would I receive funding?

• Solution briefs due: February 26, 2026 @ 23:59:59 US Eastern Time.
• Phase 2 live demonstration: Planned for Spring 2026 at Yuma Proving Ground, AZ.
Funding awards are typically announced after Phase 1 evaluation and negotiation, which can occur within DIU’s standard 60-90 day CSO window once a solution is selected for full proposal submission.

Where does this funding come from?

This project is funded by the U.S. Department of Defense (DoD) and administered by the Defense Innovation Unit (DIU) through its Commercial Solutions Opening (CSO) process, leveraging Other Transaction Authority (OTA).

Who is eligible to apply?

Any commercial entity or individual with a mature sensing solution or applicable commercial-ready technology can respond. DIU encourages both established defense contractors and nontraditional vendors to submit.

What companies and projects are likely to win?

Competitively favored proposals will:
• Address either or both LOEs fully and clearly.
• Demonstrate proven sensing performance (e.g., range, tracking, classification).
• Provide integration paths with DoD systems and readiness for live demonstration.
• Be commercially mature or near production — especially for Homeland Defense sensing.

Are there any restrictions I should know about?

• If selected for live demonstrations, companies must coordinate security protocols (varies for U.S. vs. non-U.S. citizens) and supply a DD Form 1494 with the Phase 1 proposal.

• Proposals must comply with DoD cybersecurity frameworks (e.g., RMF and ATO).

• Nontraditional defense contractors may enable faster OT awards; traditional contractors might need a cost share per DIU CSO rules.

How long will it take me to prepare an application?

Expect 2–6 weeks to prepare a compelling solution brief depending on:
• Technical readiness of your system.
• Teaming arrangements and integration plans.
• Supporting data on detection performance.
• Required compliance forms (e.g., DD 1494).

How can BW&CO help?

BW&CO can help you:
• Translate your technical capabilities into a competitive DIU solution brief.
• Strategize on Line of Effort selection and demo readiness.
• Prepare compliance documentation and security coordination plans.
• Draft a high-impact live demonstration plan that aligns with DIU and DoD expectations.

How much would BW&CO Charge?

We have an hourly rate to strategize, review, and edit applications of $250.

Additional Resources

Review the solicitation here.

DARPA BTO: Protean

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

DARPA’s Biological Technologies Office has released DARPARA2601: Protean, a high-impact research announcement focused on developing next-generation medical countermeasures that protect critical human proteins from chemical threat agents. This program aims to create prophylactics (and optionally therapeutics) that protect protein function against chemical threat challenges over 10,000x LD50s . Abstracts are due March 12th, 2026 at 4:00pm ET.

How much funding would I receive?

• Award instruments: Cooperative Agreements or Research Other Transactions (OTs)

• Period of performance: 33 months total

  • Phase 1 (Base): 18 months

  • Phase 2 (Option): 15 months

• Funding levels will depend on proposal quality and availability of funds.

What could I use the funding for?

Funding must support work aligned with Protean’s objective: restoring or protecting protein function against chemical threat agents at the mechanistic level .

Focus Areas (You must propose both phases)

You may propose in one or more of the following:

1. Nerve agents

2. Synthetic opioids

3. Ion channel toxins

Work must target DoD-relevant proteins such as:

• Acetylcholinesterase

• Mu Opioid Receptor

• Ion channels

Phase 1 – Non-Classical Protection (18 months)

Funding may support:

• Discovery of novel regulatory points in protein conformational landscapes

• Identification of distal regulatory sites (>1 required by Month 6 milestone)

• Structural biology and computational modeling of bound/unbound conformations

• Experimental validation of novel conformational states

• Mechanistic characterization of intoxication pathways

• In vitro demonstration of functional rescue or protection

• Demonstrating:

  • 10-fold decrease in threat simulant binding affinity (Month 12)

  • 10x increase in ED50 of >3 threat surrogates (Month 16)

End of Phase 1 requires in vitro evaluation by a government Test & Evaluation (T&E) partner .

Phase 2 – Countermeasure Design (15 months)

Funding may support:

• Structure-based or ligand-based drug design

• Optimization of non-competitive chemical matter

• In vitro and in vivo efficacy improvements

• Pharmacokinetics and pharmacodynamics studies

• ADME validation

• Safety and acute toxicity screening

• In vivo rodent validation against real CWAs

Key metrics include:

• 1,000x increase in ED50 in vitro (Month 24)

• LD50 with intervention >1000x baseline (Month 24, rodent model)

• 10,000x increase in ED50 in vitro (Month 30)

• LD50 with intervention >10,000x baseline exposure (Month 33, rodent model)

Are there any additional benefits I would receive?

• Access to government Test & Evaluation (T&E) partners for real chemical warfare agent testing

• Potential use of flexible Other Transaction (OT) authority

• Early technical feedback via invitation-only pre-award sessions (if selected after Gate 1)

• Opportunity for DoD transition and chemical/biological defense positioning

What is the timeline to apply and when would I receive funding?

Key Dates:

• Posting Date: February 11th, 2026

• Protean Virtual Proposers Day: February 20th, 2026

• Question Submittal Closed: March 9th, 2026 by 4:00 PM ET

• Gate 1 Due Date (Abstract): March 12th, 2026 by 4:00 PM ET

• Gate 2 Due Date (Full Proposal): May 7th, 2026 by 4:00 PM ET

Gate 1 selection is required to submit a full proposal.

The program period of performance is 33 months .

Where does this funding come from?

Funding comes from the Defense Advanced Research Projects Agency (DARPA), Biological Technologies Office (BTO) .

Funding Opportunity Number: DARPARA2601
NAICS Code: 541714

Who is eligible to apply?

All responsible sources capable of satisfying the Government's needs, including U.S. and non-U.S. sources, may submit proposals .

• Historically Black Colleges and Universities, small businesses, small-disadvantaged businesses, and minority institutions are encouraged to apply .

• Proposers must be registered in SAM and have a valid Unique Entity ID .

• Proposals must be UNCLASSIFIED or CUI .

• FFRDCs, UARCs, and Government entities must contact the agency POC prior to submission to discuss eligibility , competitive proposals will:

• Present highly innovative, non-classical mechanistic approaches

• Identify >1 novel distal regulatory site by Month 6

• Demonstrate feasibility across both Phase 1 and Phase 2 metrics

• Provide experimentally validated structural insights (not purely computational)

• Show credible in vivo translation plans

• Demonstrate strong relevance to DoD chemical and biological defense

Proposals that fail to address both phases will be deemed non-conforming .

Are there any restrictions I should know about?

Key restrictions include:

• Must propose to both Phases

• Must comply with Controlled Unclassified Information (CUI) handling requirements (NIST 800-171 compliant systems)

• IP ownership or licensing must be clearly documented

• Potential publication restrictions for non-fundamental research

• Organizational Conflict of Interest disclosures required

• No classified submissions allowed at Gate 1

How long will it take me to prepare an application?

Gate 1 is intentionally streamlined:

• 10-minute Video Abstract (max 5 slides)

• 5-page Abbreviated Technical Volume

• Rough Order of Magnitude cost estimate

Most well-prepared teams should expect 3–6 weeks to develop a competitive Gate 1 submission, depending on technical maturity and team alignment.

Gate 2 preparation will require significantly more effort if invited.

How can BW&CO help?

We help founders and research teams:

• Reverse-engineer DARPA evaluation criteria

• Position non-classical mechanisms to align with milestone language

• Translate structural biology and modeling approaches into milestone-driven narratives

• Architect Phase 1 → Phase 2 transition logic

• Draft Gate 1 materials that maximize selection probability

• Build credible in vivo translation pathways

Our role is to make sure your science aligns exactly with DARPA’s stated metrics and exclusion criteria.

How much would BW&CO Charge?

We charge a flat $4,000 fee to submit the pre-proposal for Gate 1. We also have an hourly rate to strategize, review, and edit applications of $250.

Additional Resources

Review the solicitation here.

BRAIN Initiative: Theories, Models and Methods for Analysis of Complex Data from the Brain

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

The NIH BRAIN Initiative: Theories, Models and Methods for Analysis of Complex Data from the Brain (RFA-DA-27-004) is a competitive R01 research grant supporting the development of innovative theories, computational models, and analytical tools to advance understanding of brain function from complex neuroscience data. This funding is part of the NIH BRAIN Initiative, aiming to transform neuroscience through quantitative, predictive frameworks. Applications are due as soon as October 6th, 2026.

How much funding would I receive?

Application budgets are not limited, but NIH expects direct costs of approximately $150,000 – $350,000 per year.

Awards are for up to 3 years of support.

NIH anticipates funding multiple awards each cycle, depending on score and available appropriations.

What could I use the funding for?

Theories of brain function

Development of predictive, mathematically-grounded theories explaining how behavior arises from neural structure, circuit dynamics, computation, cognition, and environmental variables. Examples include:

• Theories of embodied computation that anchor the neural representation of sensory, cognitive, and motor variables to an individual/animal’s ongoing interactions with the environment through dynamic, moment-to-moment, circular, and iterative processes.

• Theories that bridge multiple scales of spatial organization (e.g., molecular, synaptic, cellular, circuit, systems) and/or temporal dynamics (e.g., milliseconds to lifetimes) to generate testable predictions of brain-behavior links or cognitive function.

• Theories linking circuit dynamics and function to specific properties of cell types or anatomical connections, identifying general rules, scaling principles, and contributions of specific circuit motifs to computation.

• Theories elucidating fundamental computational principles employed by biological neural networks, potentially drawing inspiration from or contrasting with artificial networks, but firmly grounded in biological constraints (e.g., neuronal/synaptic dynamics, connectivity patterns, metabolic limits, specific cell-type properties, learning rules).

Computational models of neural and behavioral dynamics

Development and validation of quantitative models that are mechanistically grounded, interpretable, predictive, and rigorously tested against neural and behavioral data. Examples include:

• Mechanistic, interpretable, and/or predictive models of neural dynamics, circuit function, or brain-behavior links that integrate biological details with computational principles.

• Models that integrate knowledge across multiple levels (e.g., linking behavior to neural population activity and cellular/circuit properties).

• Models of cognitive processing (e.g., sensory coding, decision-making, motor control, learning, memory) that are mechanistically grounded in identified circuit elements and dynamics, make quantitative predictions, and are rigorously tested against neural and behavioral data, potentially under ecologically relevant or challenging conditions (e.g., limited information, dynamic environments).

• Development and analysis of neural-inspired computational architectures or artificial intelligence/machine learning systems explicitly designed to gain novel insights into brain function.

Methods for complex data analysis

Development of novel computational, statistical, and analytical techniques designed to extract key insights from complex, large-scale neuroscience datasets. Examples include:

• Development of innovative and scalable computational/statistical methods for dimensionality reduction, identifying latent structure, disentangling contributing factors (e.g., sensory, motor, cognitive, state variables), extracting key dynamical features, or characterizing information flow within large, complex neural and behavioral datasets.

• Novel approaches for principled data fusion and assimilation to quantitatively integrate heterogeneous datasets (e.g., linking behavior with multi-regional activity, anatomical connectivity, and cell-type information) to infer new theories of brain function, or to constrain and validate multi-scale computational models.

• Novel statistical/signal processing methods (e.g., component analysis, graphical models, compressed sensing) to track structure in neural data and link to biophysical signals for mechanistic insights across scales.

Are there any additional benefits I would receive?

• Collaboration with NIH program staff and participation in the broader BRAIN Initiative network.

• Tools developed are expected to be shared with the neuroscience community, enhancing visibility and impact.

What is the timeline to apply and when would I receive funding?

Application Due Dates (all by 5:00 PM local time):

• Cycle 2: October 6, 2026

• Cycle 3: October 6, 2027

Expiration of this NOFO: November 9, 2027

Following review, awards generally begin in March–July of the year after submission.

Where does this funding come from?

This funding is provided by the National Institutes of Health (NIH) through multiple participating Institutes and Centers under the NIH BRAIN Initiative, including NIDA, NEI, NIA, NIAAA, NIBIB, NICHD, NIDCD, NIMH, NINDS, and NCCIH.

Who is eligible to apply?

Eligible applicant organizations include:

• Higher Education Institutions

• Nonprofit organizations

• For-profit organizations (including small businesses)

• Local/state governments and tribal governments

• Foreign organizations (with restrictions on foreign subawards)

• Other research or non-profit entities

Eligible individuals are those qualified to lead the proposed research.

What companies and projects are likely to win?

Strong applicants typically:

• Propose novel and rigorous theoretical or computational frameworks.

• Demonstrate deep expertise in neuroscience, modeling, or computational analysis.

• Have clear plans to validate and share tools with the research community.

• Show relevance to BRAIN Initiative goals and the integration of complex datasets.

Are there any restrictions I should know about?

• Clinical trials are not allowed—only research on theory/model/method development.

• Proposed work must go beyond simple data collection and focus on quantitative theories or analytical tools.

• Foreign subawards are not permitted; collaborations must be unfunded or through other compliant mechanisms.

How long will it take me to prepare an application?

Plan 4-5 months minimum for:

• Concept development

• Budget preparation

• Letters of support and team coordination

• Registering with Grants.gov and eRA Commons (if not already completed)

NIH registration processes can take 6+ weeks, so start early.

How can BW&CO help?

BW&CO can assist with:

• Translating your science aims into NIH-ready specific aims.

• Coordinating NIH format and submission requirements.

• Aligning proposal with BRAIN Initiative priorities.

How much would BW&CO Charge?

We have both fractional engagements ($250 an hour) and full engagements ($13,000 + 5%) available.

Additional Resources

Review the solicitation here.

NIDDK: Advancing Research on the Application of Digital Health Technology to the Management of Type 2 Diabetes

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

NIH/NIDDK is seeking investigator teams to lead clinical trials testing digital health technologies in Type 2 Diabetes management. This R01 requires a clinical trial and aims to build evidence on how digital tools (e.g., continuous glucose monitors, mobile apps, telehealth, wearables) can improve glycemic and related outcomes in people with Type 2 Diabetes. Applications are due October 6, 2026 by 5:00 PM local time — plan ahead to prepare a full clinical trial proposal that adheres to NIH requirements.

How much funding would I receive?

Funds anticipated: Direct costs ~

• $1.5M in FY2026,

• $3.0M in FY2027-2030,

• $1.5M in FY2031.

Award budget: Not capped — must reflect actual needs of the proposed clinical trial project.

Project period: Up to 5 years.

What could I use the funding for?

General principles:

• Multimodality DHT interventions that for example, combine CGM concurrently with other digital interventions in a virtual remote continuous care intervention, though not required, are of particular interest to this NOFO.

• All investigators are expected to include meaningful engagement approaches with the relevant research population in designing and implementing the proposed trial. This may involve engagement with patients, family members or caregivers, community members, community-based organization, clinicians and other care providers, health care systems, or other relevant partners throughout the research process. Meaningful engagement must entail more than focus groups, surveys, or other activities where partners are only involved as participants or respondents. Engagement must be designed to ensure that the research is practical and aligns with partners' preferences and values. Meaningful collaboration will lead to optimal trial recruitment and conduct as well as potential for future dissemination and sustainability. 

• Multiple digital interventions have applicability to management of both T1 and T2 diabetes and these DHT interventions are of interest to this NOFO.

• Partnering with industry providers of virtual diabetes clinic offerings is allowed but not required.

• Clinical trials funded in response to this NOFO are expected to provide efficacy data that will enable future large multicenter clinical effectiveness studies on the application of DHT to PWD.

Examples of DHT interventions to be tested include, but are not limited to:

• Continuous glucose monitoring:

  • Studies on the efficacy of CGM in T2D, including in PWD not taking insulin

  • Studies on the utility of CGM in persons with prediabetes, for example, interventions that prevent the progression of prediabetes to diabetes

  • Studies examining the role of CGM in monitoring and adapting dietary interventions

  • Studies on the dose and duration of CGM usage necessary to effect change in health activation and healthy behaviors

  • Studies to assess and promote the accessibility, adoption and sustainability of CGM interventions

  • Studies assessing and improving the integration of CGM into clinic workflow, particularly in primary care settings

• Activity monitoring:

  • Studies examining the role of digital monitoring of activity on improvement of glycemia and other metabolic parameters in PWD

• Digital nutritional monitoring

  • The use of mobile applications to facilitate measures of macronutrient content of meals in PWD, and the impact of these interventions on diabetes-specific outcomes.

• Telemedicine, directed text messaging, patient portals, and peer-support

  • Studies assessing the incorporation of virtual communication into a multimodality virtual diabetes clinic model

  • Studies examining the influence of digital methods of multi-touchpoint peer support on glycemic and non-glycemic diabetes-specific outcomes

• Gaming and gamification

  • Studies examining the effect of digital gamification on the uptake and sustained adoption of diabetes education to improve knowledge and promote self-care behaviors (dietary, activity, and medication adherence) in a manner that improves diabetes-specific outcomes

• DHT adoption and sustainment

  • Studies examining factors predicting and improving patient engagement, adoption, and sustained use and utility of DHT interventions in PWD, and phenotyping according to acceptance of different modalities of DHT (CGM, wearables, telehealth, etc.) 

  • Studies examining the role of interventions to improve access of DHT for all PWD; to evaluate, measure, and improve digital literacy; and examine the influence of health beliefs and trust in the HCS on the successful utilization of all forms of DHT, including telemedicine 

  • Studies examining the influence of DHT interventions on patient engagement, self-empowerment, diabetes distress, and quality of life using validated measures.

  • Studies including a specific aim to determine the cost-effectiveness of specific DHT interventions in PWD 

  • Studies examining the effect of incentivizing PWD, providers and the health care system to incorporate DHT into diabetes management 

  • Studies examining the role of digital health navigators, including AI-based systems, in improving the acceptability and sustainability digital health interventions in PWD 

Are there any additional benefits I would receive?

• Potential to position your digital health intervention for future large multicenter effectiveness studies if early clinical evidence is strong.

• Grant support includes access to NIH peer review and scientific oversight.

Note: There’s no letter of intent required.

What is the timeline to apply and when would I receive funding?

Posted Date: September 17, 2025

Application Due: October 6, 2026 by 5:00 PM local time

Where does this funding come from?

NIH — National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), part of the U.S. Department of Health and Human Services.

CFDA: 93.847 — Diabetes, Digestive, and Kidney Diseases Extramural Research.

Who is eligible to apply?

Eligible domestic applicants include:

• Higher education institutions (public/private)

• Nonprofits (with or without 501(c)(3) status)

• For-profit organizations (including small businesses)

• Local and state governments

• Tribal governments/organizations

• Public housing authorities

• Independent school districts

• U.S. Federal agencies are eligible

Foreign organizations are NOT eligible.

What companies and projects are likely to win?

Strong proposals will have:

• A clearly defined clinical trial plan with measurable outcomes.

• Meaningful patient, provider, and community engagement integrated into design and implementation.

• Digital interventions that are ready for testing, not just conceptual.

• Evidence of feasibility and mechanism for adoption in real-world settings.

Are there any restrictions I should know about?

Not responsive:

• Projects developing new digital devices or algorithms.

• Studies focused on automated insulin delivery, artificial pancreas, or hybrid closed-loop tech.

• Research using DHT data only for subtyping/classification.

• Mechanistic trials that are not testing an intervention’s effectiveness.

How long will it take me to prepare an application?

Typical NIH R01 applications take several months to:

• Develop a rigorous clinical trial design,

• Form research team + collaborations,

• Draft research strategy + human subjects sections,

• Complete registrations (SAM, eRA Commons).

Most institutions begin 6-12 months before due date.

How can BW&CO help?

BW&CO can assist with:

• Translating this technical RFA into a clinical trial proposal roadmap.

• Crafting aims, hypotheses, and outcomes tables tailored to NIH review criteria.

• Aligning digital intervention strengths with NIH priorities.

• Supporting human subjects/clinical trial documentation and compliance.

How much would BW&CO Charge?

We have both fractional engagements ($250 an hour) and full engagements ($13,000 + 5%) available.

Additional Resources

Review the solicitation here.

Pennsylvania Agricultural Innovation Grant Program

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

Deadline Approaching: Apply by 11:59 PM ET on April 18, 2026 — this competitive state grant is now open and closing soon. The Pennsylvania Agricultural Innovation Grant Program offers a $10 million investment to help farmers, agricultural businesses, and innovators deploy new technologies, improve sustainability, and scale solutions that enhance production, conservation, and energy efficiency statewide. Applications must be submitted online via the Single Application for Assistance between 8 AM ET Feb 2, 2026 and 11:59 PM ET April 18, 2026.

How much funding would I receive?

Total funding available: $10 million in the 2025–26 round.

Grant types & award sizes:

• Innovation Planning Project Grant: $7,500–$50,000 (30% non-state match required)

• Onsite Project Grant: $5,000–$200,000 (50% non-state match required)

• Regional Impact Project Grant: $100,000–$2,000,000 (50% non-state match required; must benefit ≥2 eligible persons/businesses)

What could I use the funding for?

Funding reimburses project planning, implementation, and regional impact innovations in the following priority areas:

Key eligible innovation areas:

• Improve energy efficiency and water quality on farms

• Reduce water use, odors, or solid waste

• Improve production, processing, commercialization, or utilization of agricultural commodities

• Produce energy from manure, food waste, biomass

• Deploy low-carbon or no-carbon energy equipment

• Farm management technologies (e.g., diagnostics, data tools)

• Process efficiency tools (sorting, grading, etc.)

• Biosecurity and plant/animal health innovations

• Cybersecurity and data analytics solutions

Are there any additional benefits I would receive?

Beyond direct funding, grantees will:

• Gain credibility and visibility as part of Pennsylvania’s nation-leading innovation portfolio

• Support broader economic growth and sustainability across the Commonwealth’s agricultural sector

• Build proof points to attract follow-on investment and partners

What is the timeline to apply and when would I receive funding?

Application window:

• Opens: 8 AM ET, February 2, 2026

• Closes: 11:59 PM ET, April 18, 2026
  Applications must be submitted online through the Single Application for Assistance system; late submissions will not be reviewed.

Funding decisions and reimbursement timelines depend on PDA’s review process and grant execution, typically following award announcements after April 2026.

Where does this funding come from?

Funding is part of the Commonwealth of Pennsylvania’s 2025–26 budget under the Shapiro Administration, investing $10 million in the second round of the nation’s first Agricultural Innovation Grant Program to strengthen farm sustainability, technology adoption, and clean energy development.

Who is eligible to apply?

Eligible applicants include:

• Individuals who grow an agricultural commodity with anticipated sales of > $2,000/year

• Individuals who process an agricultural commodity with anticipated sales of > $10,000/year

• Providers of technical services to farmers (e.g., conservation, veterinary care, engineering, farm management)

• Persons or cooperative associations that use agricultural commodities to create products or energy

What companies and projects are likely to win?

Competitive proposals will:

• Clearly align with innovation priority areas outlined above

• Demonstrate measurable impact (economic, environmental, technological)

• Include strong budgets, timelines, and success metrics

• Show scalable and practical outcomes for Pennsylvania agriculture

Projects with broad applicability (e.g., renewable energy systems, advanced processing technologies, farm-scale data tools) and those that deliver regional benefits are especially strong candidates.

Are there any restrictions I should know about?

Applicants must:

• Use non-state matching funds at required levels

• Submit paid receipts for reimbursement requests

• Ensure projects are located in Pennsylvania and comply with all state laws and regulations

• Only costs incurred during the contract period are eligible for reimbursement

How long will it take me to prepare an application?

Preparation time depends on project complexity:

• Simple planning projects: 1–3 weeks

• Onsite and regional projects with detailed budgets and partners: 2–6+ weeks
  You must gather narratives, budgets, metrics, match commitments, and letters of support before the April 18 deadline.

How can BW&CO help?

BW&CO can assist by:

• Translating your innovation idea into a compelling application narrative

• Structuring budgets and measurable outcomes to meet PDA criteria

• Identifying matching fund strategies and partner letters

• Reviewing drafts for clarity, cohesion, and competitiveness

How much would BW&CO Charge?

Fractional support is $300 per hour.

For startups, we offer a discounted rate of $250 per hour to make top-tier consulting more accessible while maintaining the same level of strategic guidance and proposal quality.

Additional Resources

Review the solicitation here.

ARPA-H SSO: “AGENTIC AI-ENABLED CARDIOVASCULAR CARE TRANSFORMATION” (ADVOCATE)

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

ARPA-H is now accepting proposals for ADVOCATE: Agentic AI-Enabled Cardiovascular Care Transformation, a major new Innovative Solutions Opening (ISO) focused on deploying autonomous, FDA-regulated clinical AI agents for cardiovascular disease (CVD) care at national scale.

This program is designed to fund teams that can build, validate, and deploy patient-facing AI agents, paired with independent supervisory AI, and integrate them directly into real healthcare systems. Selected performers will work closely with FDA, large health systems, and ARPA-H leadership to establish a blueprint for scalable, reimbursable agentic AI in healthcare. A Solution Summary is mandatory and is due February 27, 2026, at 5:00 PM EST. Full proposals are by invitation only and are due April 1, 2026, at 5:00 PM EST.

How much funding would I receive?

• Total award size: Not specified in the solicitation

• Number of awards: Multiple awards anticipated

• Funding mechanism: Other Transaction (OT) Agreements

• Program length: Up to 39 months

  • Phase 1A: 12 months

  • Phase 1B: 12 months (option)

  • Phase 2: 15 months (option)

What could I use the funding for?

Funding must support development, validation, and deployment of agentic AI systems for cardiovascular care, aligned to one or more of the following Technical Areas (TAs):

TA1 — CVD Agent (Patient-Facing Clinical AI)

• Autonomous or semi-autonomous AI agents that:

  • Provide diagnostic and treatment assistance

  • Adjust prescriptions for CV conditions (FDA medical device)

  • Integrate real-time EHR and wearable data

  • Deliver 24/7 outpatient care management

• Clinical reasoning using multimodal inputs (text, voice, image, video)

• FDA regulatory engagement and authorization

• Deployment into real health systems for scalability studies

TA2 — Supervisory Agent (AI Oversight & Control)

• Disease-agnostic AI that:

  • Monitors safety, accuracy, uncertainty, and risk of clinical AI

  • Enables real-time control and auditability

  • Supports FDA Medical Device Development Tool (MDDT) qualification

• Continuous post-market monitoring functionality

• Strong preference for open-source solutions

TA3 — Scaled Implementation (Health Systems Only)

• Integration of TA1 and TA2 agents into live clinical workflows

• Access to EHR production and pre-production environments

• Execution of large-scale Scalability Studies

• Clinical outcome, cost, and reimbursement evidence generation

Are there any additional benefits I would receive?

Selected teams receive:

• Direct engagement with FDA throughout development

• Access to real EHR data, clinicians, and patients (via TA3 performers)

• Participation in large, ARPA-H-funded scalability studies

• Validation by an independent IV&V partner

• Visibility with payers and CMS-relevant evidence generation

• Potential facilitation of investor engagement by ARPA-H

What is the timeline to apply and when would I receive funding?

Key dates (firm):

• Posting date: January 13, 2026

• Proposers’ Day: January 23, 2026 (8:30 AM – 5:00 PM EST)

• Proposers’ Day registration deadline:

  • In-person: January 21, 2026, at 5:00 PM EST

  • Virtual: January 21, 2026, at 5:00 PM EST

• Solution Summary due: February 27, 2026, at 5:00 PM EST

• Full proposal due (if invited): April 1, 2026, at 5:00 PM EST

Funding timing after submission is not specified and is contingent on negotiations and down-selection decisions.

Where does this funding come from?

• Agency: Advanced Research Projects Agency for Health (ARPA-H)

• Office: Scalable Solutions Office (SSO)

• Authority: Other Transaction (OT)

Who is eligible to apply?

Eligible applicants include:

• U.S. startups and growth-stage companies

• Universities and academic teams

• Non-profit organizations

• Non-federal research organizations

Not eligible:

• Federally Funded Research and Development Centers (FFRDCs)

• Federal government entities or employees (as performers)

• Entities from covered foreign countries or foreign entities of concern

• Organizations with unmitigable ARPA-H conflicts of interest

TA3 applicants cannot apply to TA1 or TA2.

What companies and projects are likely to win?

ARPA-H is explicitly seeking teams that:

• Are building agentic (not rules-based) clinical AI

• Can meet FDA medical device or MDDT requirements

• Have real experience integrating with EHRs and health systems

• Can demonstrate a path to non-inferiority vs cardiologists

• Are prepared for open data sharing and multi-party collaboration

• Can scale beyond pilots into national deployment

Incremental clinical decision support tools are unlikely to be competitive.

Are there any restrictions I should know about?

Key restrictions include:

• Foundation models cannot be developed from scratch

• Solutions must be interoperable with other agents

• Clinical AI must pursue FDA authorization or qualification

• Extensive data-sharing and collaboration are mandatory

• Foreign talent, ownership, or funding risks are heavily scrutinized

• TA1 and TA2 proposals must remain technically independent

How long will it take me to prepare an application?

• Solution Summary: ~2–4 weeks for competitive teams

• Full Proposal: ~6–10 weeks if invited

Team formation, regulatory strategy, and data architecture must be addressed early.

How can BW&CO help?

BW&CO helps teams:

• Translate ADVOCATE requirements into a clear, fundable narrative

• Position technical capabilities against TA-specific metrics

• Shape FDA and commercialization strategy language

• Design compliant multi-party teaming structures

• Avoid common ARPA-H disqualifiers

How much would BW&CO Charge?

Fractional support is $300 per hour.

For startups, we offer a discounted rate of $250 per hour to make top-tier consulting more accessible while maintaining the same level of strategic guidance and proposal quality.

Additional Resources

Review the solicitation here.

Development of Radiological/Nuclear Medical Countermeasures (MCMs) And Biodosimetry Devices

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

The National Institute of Allergy and Infectious Diseases (NIAID) is actively seeking proposals to develop radiological/nuclear medical countermeasures (MCMs) or biodosimetry biomarkers and devices to support response to a radiological or nuclear public health emergency. This is a cost-reimbursement contract opportunity, not a grant, and is intended to advance technologies that reduce mortality, guide triage, and improve treatment decisions after radiation exposure. Proposals are due May 4th, 2026.

How much funding would I receive?

• Total contract value: Not specified (listed as “TBD” in the solicitation)

• Contract type: Cost-reimbursement with fixed fee

• Base period funding: TBD

• Option periods: Up to two option periods, funding TBD

Because dollar amounts are not pre-set, funding levels will depend on scope, cost realism, and negotiation with NIAID.

What could I use the funding for?

Funding must support one of the two objectives below.

A. Radiological/Nuclear Medical Countermeasures (MCMs)

Funding may be used to develop safe and effective MCMs that:

• Mitigate and/or treat normal tissue injuries caused by ionizing radiation

• Reduce radiation-associated mortality or major morbidities

• Are efficacious 24 hours or later post-exposure (MCMs intended for immediate post-exposure use are generally excluded, unless otherwise noted in the objectives)

B. Biodosimetry Biomarkers and Devices

Funding may be used to advance biodosimetry biomarkers and/or devices that:

• Inform triage and treatment strategies

• Are suitable for use during a radiation public health emergency

Allowable Cost Categories (with Contracting Officer approval where required) include:

• Personnel and research labor

• Subcontracts and consultants

• Travel (including foreign travel)

• Patient care costs

• Equipment and materials

• Printing and reporting

• Research-related conferences and meetings

Are there any additional benefits I would receive?

In addition to funding, awardees receive:

• A direct contractual relationship with NIH/NIAID

• Eligibility for option period extensions at the government’s discretion

• The ability to generate patents, subject to federal invention regulations

• Increased credibility for future BARDA, NIH, and DoD opportunities

What is the timeline to apply and when would I receive funding?

• Solicitation issued: February 10, 2026

• Questions due: March 3, 2026 (recommended)

• Proposal deadline: May 4, 2026 at 3:00 PM ET

• Contract period of performance: TBD

• Funding start: After award and contract execution (date not specified)on maturity or need

Where does this funding come from?

This funding is provided by the National Institute of Allergy and Infectious Diseases (NIAID) within the National Institutes of Health (NIH), U.S. Department of Health and Human Services.

Who is eligible to apply?

Eligible applicants include:

• For-profit companies

• Small businesses

• Nonprofits and research institutions

• Universities

• Domestic and foreign entities

Applicants must be registered in SAM prior to award.

What companies and projects are likely to win?

NIAID is looking for teams that:

• Have strong scientific and technical rationale

• Address clearly defined unmet needs in radiation response

• Can demonstrate feasible development and execution plans

• Align tightly with the Research and Technical Objectives in the solicitation

Projects are evaluated primarily on technical merit, relevance to agency priorities, and availability of funds.

Are there any restrictions I should know about?

Key restrictions include:

• You may only submit one focus per proposal (MCM or biodosimetry)

• Certain costs require prior Contracting Officer approval

• Strict compliance with human subjects, animal welfare, data sharing, and publication policies

• Funds may not be used for prohibited activities (e.g., abortion, human embryo research, needle exchange, promotion of controlled substances legalization)

How long will it take me to prepare an application?

Most companies should plan for 8–12+ weeks to prepare:

• A full technical proposal and Statement of Work

• A detailed cost proposal and supporting documentation

• Required representations, certifications, and attachments

How can BW&CO help?

BW&CO can:

• Translate the BAA into a clear win strategy

• Define scope, milestones, and budget that survive NIH negotiation

• Draft or review the technical and business proposals

• Ensure compliance with NIH contract requirements

• Position your company for option periods and follow-on funding

How much would BW&CO Charge?

Fractional support is $300 per hour.

For startups, we offer a discounted rate of $250 per hour to make top-tier consulting more accessible while maintaining the same level of strategic guidance and proposal quality.

Additional Resources

Review the solicitation here.

Air Force Cryptologic Office (AFCO) Commercial Solutions Opening (CSO)

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

The Air Force Cryptologic Office (AFCO) is actively seeking innovative commercial technologies to support U.S. Air Force cyberspace intelligence, electromagnetic warfare, information operations, and multi-domain operations. This Commercial Solutions Opening (CSO) is designed to move fast, fund mature technologies applied in novel ways, and support field demonstrations—ideally within one year.

How much funding would I receive?

AFCO expects to make individual awards ranging from:

• $50,000 to $50,000,000 over the full period of performance

These amounts are not strict limits. Proposals over $15,000,000 must include phased options that allow for incremental funding. All awards are subject to the availability of funds.

What could I use the funding for?

Funding may be used to develop, demonstrate, test, or deploy innovative commercial technologies aligned with AFCO’s mission areas. Proposals must address one or more of the following capability areas:

AFCO-CM-001, ELECTROMAGNETIC WARFARE (EW)

• Electromagnetic attack, support, and protection

• EW data fusion and advanced signal processing

• Cognitive EW and AI/ML-enabled techniques

• EW battle management and waveform generation

AFCO-CM-002, INFORMATION OPERATIONS (IO)

• Technologies that affect adversary decision-making

• Capabilities targeting informational, physical, or cognitive dimensions

• Generative AI or autonomous AI applied to the information environment

AFCO-CM-003, Electromagnetic Digital Communications

• Free-space and space-based digital communications

• Access, denial, disruption, degradation, deception, or destruction of communications

• Novel approaches emphasizing extensibility over single-purpose solutions

AFCO-CM-004, Multi-Domain Innovation

• Integrated effects across EW, cyberspace, ISR, and information operations

• Automated and synchronized multi-domain operational capabilities

Are there any additional benefits I would receive?

In addition to funding, successful companies may receive:

• Direct engagement with Air Force technical and operational stakeholders

• Opportunities for follow-on contracts or Other Transactions (OTs)

• Potential multi-year periods of performance (up to five years)

• A clear pathway from prototype to operational relevancest Proposal and SOW).

What is the timeline to apply and when would I receive funding?

• Phase I: Quad Chart and White Paper may be submitted at any time before September 30, 2026

• Phase II: Only by invitation from the Contracting Officer

• Proposal preparation window (Phase II): 30 calendar days from invitation

• Expected contract start: Approximately 90 days after proposal submission

Period of performance:

• Typically 1–5 years, with exceptions considered based on maturity or need

Where does this funding come from?

Funding is provided by the Air Force Cryptologic Office (AFCO), Cyberspace ISR and Multi-Domain Innovation Division, under the U.S. Department of the Air Force.

Awards may be issued as:

• Firm Fixed Price (FFP) contracts

• Fixed Price Incentive (FPI) contracts

• Other Transactions (OTs) under 10 U.S.C. §2371bal Medicines).

Who is eligible to apply?

Eligible applicants include:

• U.S.-based commercial companies

• Small businesses and non-traditional defense contractors

• Companies offering commercial items, technologies, or services

To receive an award, companies must:

• Be registered in SAM.gov

• Be considered responsible under FAR Part 9.1

• Meet any security clearance requirements if proposing classified work

What companies and projects are likely to win?

Successful proposals typically:

• Apply mature technologies in novel ways

• Demonstrate clear relevance to AFCO mission needs

• Support field demonstrations within one year (ideally)

• Offer measurable improvements to operational effectiveness

• Align with open architecture approaches (e.g., SOSA, OMS/UCI, modular software/hardware)

Are there any restrictions I should know about?

Yes. Key restrictions include:

• All submissions must be commercial solutions

• Classified submissions require prior coordination

• Proposals exceeding page limits will not be evaluated

• Intellectual property assertions must follow DFARS requirements

• AFCO may partially fund, incrementally fund, or decline any proposal

How long will it take me to prepare an application?

Typical preparation times:

• Phase I (Quad Chart + White Paper): 1–3 weeks

• Phase II (if invited): 30 calendar days

The Phase II submission includes a technical proposal, statement of work, and detailed pricing.

How can BW&CO help?

BW&CO can help you:

• Rapidly assess fit against AFCO’s priority areas

• Shape your Quad Chart and White Paper for evaluator clarity

• Position your technology for Phase II invitation

• Translate technical capabilities into mission-aligned value propositions

How much would BW&CO Charge?

Fractional support is $300 per hour.

For startups, we offer a discounted rate of $250 per hour to make top-tier consulting more accessible while maintaining the same level of strategic guidance and proposal quality.

Additional Resources

Review the solicitation here.

Production of Drug Substances and Drug Products at Commercial Scale: Anti-Microbials and Large Volume Parenterals

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

BARDA (through the BioMaP-Consortium) is looking to fund commercial-scale (“population scale”) domestic production of at least one (1) key starting material (KSM), drug substance, and/or drug product—with a stated preference for Anti-Microbials and Large Volume Parenterals (LVPs). This is an Enhanced White Paper solicitation, and the deadline is March 9, 2026, 1:00 PM ET (late submissions may not be evaluated).

How much funding would I receive?

• Total estimated funding (all projects): approximately $200 million (subject to availability and adjustment).

• Award size per project is not specified in the RPP.

• The Government anticipates making multiple awards and also reserves the right to make one, multiple, or no awards.

What could I use the funding for?

Below are the uses that map directly to the RPP’s objectives and deliverables.

1) Objective A: Engineering design + study phase (design/refine the approach)

You can propose work to design and refine an end-to-end, scalable manufacturing concept that supports population-scale production, including:

• Select at least 1 target drug substance jointly with the Government (minimum entry: MRL 6), including selection rationale.

• Build a detailed list of molecules/molecule classes, required materials, systems, and equipment across manufacturing phases.

• Develop and refine an analytical/characterization and manufacturing plan for population-scale production with automated and integrated processes across design, manufacturing, testing, and analysis—intended to increase MRL to 10 and meet U.S. Pharmacopeia standards and ICH guidelines for purity, potency, safety, validation, quality, etc.

• Include an infrastructure governance framework (management structure, partnerships, scheduling considerations).

• Assess domestic market maturity and conduct a risk assessment of domestic capabilities.

• Present Objective A results and a plan for Objective B for Government approval to proceed.

2) Objective B: Demonstrate the model + population-scale manufacturing

If approved to proceed after Objective A, you can propose to:

• Develop and execute an analytical model and demonstrate manufacturing of a KSM/API progressing from MRL 6/7 to MRL 10, in compliance with USP and ICH expectations.

• Run multiple scenarios/production runs to test assumptions and identify conditions that improve or worsen:

  • Shortest time to market

  • Lowest development/deployment costs

  • Optimal time-to-market with cost tradeoffs

  • Key drivers of time and cost

  • Recommendations for future investment to enable population-scale production in real markets

• Produce required program outputs (e.g., technical batch reports, final technical report with variables/assumptions/model runs).

• The RPP also lists deliverables tied to drug products, including registration batches, completion of environmental/engineering/registration batch runs, and ANDA filings for each drug product (as applicable to your scope).

3) Program management + risk + schedule deliverables

You can include work to:

• Manage the full program (integration, coordination, milestone schedule, critical path, go/no-go criteria).

• Maintain a risk register and report risk changes.

• Deliver required monthly technical progress reports and other specified deliverables.

4) Domestic industrial base / capacity expansion (U.S. soil)

The RPP states proposals are expected to be focused on United States investments, and capacity expansion work must be executed within the continental U.S. and its Territories (even for overseas-based companies).

Are there any additional benefits I would receive?

• This is under BARDA’s BioMaP-Consortium OTA vehicle (OTA Number 75A50123D00003) and executed via Project Agreements under the consortium framework.

• Proposals rated Acceptable through Excellent but not immediately funded may be placed into an electronic “Basket” for up to 2 years, remaining eligible for award during that time (if funding becomes available and after review of a Full Cost Proposal and SOW).

What is the timeline to apply and when would I receive funding?

Key solicitation dates

• RPP Issue Date: February 6, 2026

• Virtual Teaming Speed Networking Event: February 12, 2026

• Questions due: February 18, 2026 (by 1:00 PM ET) (submit via email to biomap-contracts@ati.org)

• Enhanced White Papers due: March 9, 2026 (by 1:00 PM ET)

Award / performance timing

• Anticipated Period of Performance: not to exceed 24 months.

• Offerors should plan for PoP to begin in Quarter 3 of Government Fiscal Year 2026 (Government may change start date via negotiations).

Where does this funding come from?

• Strategic oversight is provided by BARDA.

• The RPP references program interests from:

  • ASPR IBMSC Office (Advanced Manufacturing Domain)

  • HHS Defense Production Act (DPA) Title III Program (with preference for projects strengthening security of supply for items on the FDA List of Essential Medicines).

Who is eligible to apply?

Minimum eligibility criteria (must meet):

• You must be a BioMaP-Consortium member prior to award of a Project Agreement.

• You must show demonstrated experience in scalable manufacturing of KSMs/APIs and finished product form drugs, specifically at or beyond MRL 6.

• Cost share is required to be eligible (must describe amount, whether cash or in-kind, and valuation method).

What companies and projects are likely to win?

Based on the stated evaluation factors and technical objectives, the strongest submissions will typically be those that:

• Propose a credible path to population-scale production (hundreds of millions of doses) with domestic production capacity.

• Clearly align to the preference area: Anti-Microbials and Large Volume Parenterals.

• Demonstrate capability to move from MRL 6/7 to MRL 10 with strong USP/ICH-aligned quality/compliance planning.

• Present an integrated approach (automation, analytics, validation/QC, supply chain, and governance) with clear milestones and risk controls.

• Show meaningful, well-supported cost share.

• Bring a multidisciplinary team with relevant industrial execution experience, and (encouraged) small business utilization.

Are there any restrictions I should know about?

Yes—several are explicit:

• Submission method: Enhanced White Papers must be submitted online via BIDS; no other submission methods accepted.

• Deadline enforcement: Late Enhanced White Papers may not be evaluated.

• Format limits: Enhanced White Paper maximum 15 pages (excluding cover page and specified appendices); mandatory template/headers required.

• Domestic expansion requirement: Capacity expansion work must be executed within the continental U.S. and its Territories (per Base Agreement requirement referenced in the RPP).

• DPA domestic source compliance: Offeror must be compliant with the DPA definition of a “domestic source” (50 U.S.C. 4552(7)).

• Regulatory compliance: Expected compliance with relevant FDA, DEA, USP and cGMP practices.

• Salary rate limitation: Direct salary above Federal Executive Schedule Level II is unallowable under the OTA.

• SAM.gov / UEI: A UEI from SAM.gov is required prior to award.

• Security requirements: Attachment B lists ASPR deliverables and security requirements that may be required for resulting projects.

How long will it take me to prepare an application?

What the RPP requires:

• A compliant Enhanced White Paper using the mandatory template (plus required appendices).

• Enough detail to be evaluated on Technical Approach/Solution, Relevant Experience, and a Cost/Price ROM estimate.

• A clearly described cost share package (required for eligibility).

• A credible timeline that addresses the stated Schedule Objectives (Objective A and Objective B planning within a total PoP ≤ 24 months).

Practically, teams that are already organized and have MRL 6+ manufacturing readiness typically need to pull: technical narrative, milestones, ROM build-up, teaming roles, and cost share substantiation—plus ensure consortium membership is in place prior to award.

How can BW&CO help?

BW&CO can support you by turning this RPP into a submission-ready package, including:

• A compliance-driven Enhanced White Paper outline and draft aligned to Attachment A headers

• A reviewer-style gap check against eligibility requirements (MRL, consortium membership timing, domestic source, cost share)

• A strong Objective A/Objective B story with measurable milestones and deliverable mapping

• ROM narrative support (assumptions, labor categories, subcontractor framing) and cost share packaging

• Final “red team” editing for clarity and evaluator alignment.

How much would BW&CO Charge?

Fractional support is $300 per hour.

For startups, we offer a discounted rate of $250 per hour to make top-tier consulting more accessible while maintaining the same level of strategic guidance and proposal quality.

Additional Resources

Review the solicitation here.

National Defense Stockpile (NDS) Research & Qualification BAA – DLA

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

The Defense Logistics Agency (DLA) Strategic Materials office is seeking white papers under its National Defense Stockpile (NDS) Research and Qualification Broad Agency Announcement to fund research, development, and qualification of strategic and critical materials that strengthen domestic supply chains. Awards may support early-stage research through higher-TRL qualification efforts, with individual awards up to $10 million. The BAA is open from January 30, 2026 through January 30, 2029, with white papers due no later than May 1, 2028.

How much funding would I receive?

Individual awards are expected to range from relatively small research efforts up to $10,000,000 per award, with multiple smaller awards more likely than a single large award. Phase I efforts are limited to the Simplified Acquisition Threshold ($250K) and up to 12 months, while Phase II efforts may be funded for up to $10 million with periods of performance up to 24 months.

What could I use the funding for?

Funding may be used for research, development, demonstration, and qualification activities related to strategic and critical materials according to the following priorities:

Priority 1: Antimony, Bismuth, Gallium, Germanium, REEs and REE Magnet Materials

Priority 2: Graphite, Battery Materials, Magnesium, Refractory Metals, Energetics

Priority 3: ZOC and Related Materials, Indium, PGMs, Neon, Manganese

Priority 4: High Purity Aluminum, Beryllium, Cobalt, Scandium and Yttrium, Fluorspar


Areas of interest for the above materials are:

(1) Refining, Processing, and Beneficiation:

The research of, assessment of, evaluation of, development of, demonstration of, or establishment of:

(a) Processes to enhance the quality of materials, improve efficiency of production processes, refine or benefit from material, or mitigate recurring problems.

(b) Impacts of and solutions to external “bottlenecks” in raw material supply chains addressing materials that have been delayed, duration of the shortages, effect on production lead times, prices and impact on delivery of finished products.

(c) Impacts of and solutions to internal “bottlenecks” in materials refining processes related to converting feedstock into sellable product considering issues such as incorrect or inferior feedstock, equipment failures, lack of skilled work forces, etc.

(2) Recycling, Conservation and Substitution Options:

Identification of, evaluation of, developing methods for, and establishing domestic capabilities to:

(a) Material substitutes in active use by domestic and trade-friendly international processors and manufacturers; include limitations and common issues associated with use of the substitute material.

(b) Research to develop or qualify materials as acceptable substitutes including use of existing and emerging products.

(c) Recycling opportunities, including industrial infrastructure and logistical perceived limitations.

(d) Recycle and recover neodymium iron boron (NdFeB) or Samarium Cobalt (SmCo) magnets or recovery of rare earths or its alloys. The specifications should include the total rare earth metals (TREM) present in the recycled magnets. As well as identification of energy magnetic density of the recycled magnets.

(3) Qualification of Materials:

(a) Qualification of Research to Department of Defense Programs of Record. Projects will require letters of support from known DOD Programs of Record indicating intent to utilize the qualified material upon successful completion of the work.

Are there any additional benefits I would receive?

Beyond the formal contract award, there are meaningful indirect benefits to receiving a DLA Strategic Materials award:

• Government Validation and Credibility: Selection signals technical merit and relevance to U.S. defense supply-chain priorities.

• Stronger Position in Defense Supply Chains: Successful projects can lead to qualification for DoD Programs of Record, unlocking long-term procurement opportunities.

• Nondilutive Technology Advancement: Companies can mature materials and processes without equity dilution.

• Improved Exit and Acquisition Potential: Government-validated materials qualification can increase strategic value to primes and acquirers.

What is the timeline to apply and when would I receive funding?

The BAA is open from January 30, 2026 through January 30, 2029. White papers may be submitted on a rolling basis but must be received by May 1, 2028. White papers are evaluated as received, and selected offerors may be invited to submit full proposals. All evaluations cease on August 1, 2028, and awards must be made by September 15, 2028.

Where does this funding come from?

Funding is provided by the Defense Logistics Agency (DLA) Strategic Materials program under its authority to support the National Defense Stockpile and strengthen domestic strategic and critical materials supply chains.

Who is eligible to apply?

Any responsible domestic source capable of performing the required research may submit a white paper. Eligibility includes businesses, nonprofits, and educational institutions that are registered in SAM.gov. Foreign-owned firms may participate subject to foreign disclosure review. There is no set-aside for small businesses, though small and disadvantaged businesses are encouraged to participate.

What companies and projects are likely to win?

Successful proposals typically demonstrate:

• Strong scientific and technical merit that improves strategic materials supply-chain resilience

• Clear alignment with one or more stated Areas of Interest and listed strategic materials

• Innovative, feasible, and non-duplicative technical approaches

• Qualified teams with relevant facilities, experience, and past performance

• Reasonable and realistic pricing supported by deliverables

Are there any restrictions I should know about?

White papers must be unclassified and may not contain proprietary information. A white paper submission is mandatory to be eligible for a full proposal. Projects are limited to a maximum of three years, depending on phase.

How long will it take me to prepare an application?

For first time applicants, white-papers will likely take 35 to 50 hours without BW&CO assistance.

How can BW&CO help?

Our team specializes in complex federal R&D proposals and can:

• Triple your likelihood of success through proven strategy and insider-aligned proposal development

• Reduce your time spent on the proposal by 50–80%, letting your team focus on technology and operations

• Ensure you are targeting the best opportunity for your project and positioning your company for long-term growth under Federal & State R&D Initiatives.

How much would BW&CO Charge?

Fractional support is $300 per hour.

For startups, we offer a discounted rate of $250 per hour to make top-tier consulting more accessible while maintaining the same level of strategic guidance and proposal quality.

Additional Resources

Review the solicitation here.

DIU - Containerized Autonomous Drone Delivery System (CADDS)

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

DIU’s Commercial Solutions Opening (CSO) solicitation PROJ00637 — Containerized Autonomous Drone Delivery System (CADDS) seeks innovative commercial solutions to enable rapid deployment and autonomous operation of large numbers of unmanned aerial systems (UAS) from containerized platforms. This opportunity closes February 17, 2026 at 23:59:59 US Eastern Time — urgent submission recommended.

How much funding would I receive?

The exact award amount is not specified online. DIU typically awards prototype contracts under Other Transaction (OT) authority, with budgets determined during negotiation based on solution scope and DoD partner need. Follow-on production contracts may be possible if the prototype is successful.

What could I use the funding for?

This solicitation is looking for solutions that:

• Enable rapid, large-scale UAS deployment from containerized platforms.

• Automate storage, launch, recovery, and refit for multi-agent systems.

• Provide rapid transport and emplacement using military/commercial vehicles.

• Support resilient command and control interfaces and open architecture integration.

• Reduce human operator burden and minimize required crew size.

You’d be expected to demonstrate capabilities within ~90 days of award.

Are there any additional benefits I would receive?

• Potential follow-on production contracts without additional competition under 10 U.S.C. § 4022 if the prototype succeeds.

• A fast-moving path into Department of Defense fielding and contracting.

What is the timeline to apply and when would I receive funding?

• Proposal Deadline: February 17, 2026 @ 23:59:59 US/Eastern.

• DIU typically reviews solution briefs first, then invites selected teams to pitch/submit full proposals (often within ~30 days).

• Prototype projects are generally expected to be demonstrable within ~90 days of award.

Where does this funding come from?

DIU is part of the U.S. Department of Defense, focused on accelerating commercial tech adoption for defense applications. Funding is administered under Other Transaction (OT) authority — a flexible contracting approach outside traditional FAR rules.

Who is eligible to apply?

U.S. and international vendors are eligible to respond.

1. To use an OT agreement, requirements of 10 U.S.C. § 4022 must be satisfied (e.g., contributions by nontraditional defense contractors, small business participants, or cost sharing).

What companies and projects are likely to win?

Competitive submissions will:

• Clearly align with rapid autonomous UAS deployment at scale.

• Demonstrate modularity, open architecture, and operational utility.

• Show ability to reduce human operator burden and handle austere environments.

• Present clear pathway to meet the ~90-day demonstration target.

Are there any restrictions I should know about?

Compliance with Section 889 of the John S. McCain NDAA is required for award.

1. IP is generally retained by the company, with negotiated DoD use rights.

2. OT agreements have specific cost-sharing and contractor status rules under 10 U.S.C. § 4022.

How long will it take me to prepare an application?

• Solution briefs are typically ~5 pages (or ~15 slides) and can be prepared in 1–3 weeks with focused effort.

• Full proposals (if invited) will require detailed technical and project execution plans.

How can BW&CO help?

BW&CO can assist with:

• Crafting solution briefs that clearly align with DIU’s mission and review criteria.

• Developing full OT proposals with technical, cost, and operational plans.

• Strategizing for rapid prototype demonstration and DoD transition pathways.

How much would BW&CO Charge?

Fractional support is $300 per hour.

For startups, we offer a discounted rate of $250 per hour to make top-tier consulting more accessible while maintaining the same level of strategic guidance and proposal quality.

Additional Resources

Review the solicitation here.

DIU - Sensors and Seekers For Fire Control

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

Act now — Responses due February 13, 2026 at 23:59:59 US/Eastern for Deorbit as a Service, a high-priority Defense Innovation Unit (DIU) Commercial Solutions Opening (CSO) to solve a strategic orbital debris and space sustainability challenge. This solicitation funds scalable autonomous technologies that can deorbit unprepared satellites safely and reliably, reducing orbital congestion and enabling future space operations. This is a rare fast-paced opportunity to partner with the U.S. Department of Defense (DoD) using flexible Other Transaction Authority with potential follow-on production contracts without further competition — massive market potential.

You’ll submit a Solution Brief that directly addresses specific detection, tracking, and discrimination capabilities using commercial sensing technologies. If selected, DIU can award a Prototype Other Transaction (OT) agreement and potentially a follow-on production contract if the prototype is successful.

How much funding would I receive?

DIU does not publicly list a fixed award size on this solicitation page. Funding amounts for DIU prototype OT agreements vary based on technical scope and negotiated project budgets with selected vendors.

What could I use the funding for?

Funding may be used to develop and demonstrate prototypes that meet the Government’s technical needs, including:

A. Sensor System Development

• LIDAR/LADAR, EO/IR, RF, or combined modalities that enable high-fidelity detection, tracking, and discrimination under extreme conditions.

B. Fire Control Enablement

• Systems capable of providing real-time, fire-control-quality tracking data (range, angular resolution, update rates) for engagements against ICBMs or hypersonic glide vehicles.

C. Prototyping & Demonstrations

• Bench-top or lab demonstrations within ~6–9 months.

• On-orbit demonstrations as a hosted payload within ~12–24 months (if applicable).

Are there any additional benefits I would receive?

Yes. Commercial companies participating through DIU can gain:

• Access to DoD customers and mission partners who care about real outcomes.

• A potential follow-on production contract without a new competition after satisfactory prototype completion (per 10 U.S.C. §4022(f)).

• Exposure to broader government adoption via Success Memos that other DoD entities can use.

What is the timeline to apply and when would I receive funding?

• Application Deadline:
  🔹 February 17, 2026 at 23:59:59 US/Eastern Time

  Typical DIU CSO timeline:

  • Solution Brief submission → evaluation

  • ~30 days to get invited to pitch if selected

  • Contracts negotiated and awarded typically within ~60–90 days after selection (varies).

  Prototype execution milestones generally include lab demos within 6–9 months and potential on-orbit demos within 12–24 months, as outlined by this project.

Where does this funding come from?

The funding is provided through the Department of Defense (DoD) via the Defense Innovation Unit (DIU) using its Commercial Solutions Opening (CSO) process under Other Transaction (OT) Authority (10 U.S.C. 4022).

Who is eligible to apply?

U.S. and international vendors with relevant sensor and seeker technologies.

• Companies must satisfy OT authority requirements per 10 U.S.C. 4022(d) (e.g., participation of nontraditional firms, small business involvement, or non-government funding share).

No specific size, revenue, or TRL ceiling is listed, but solutions must be technically relevant and commercially viable.

What companies and projects are likely to win?

Winners will propose solutions that demonstrate:

• High-performance sensing and discrimination across threat scenarios.

• Commercially scalable designs (design for manufacturability and low unit cost).

• Plan for integration into aerospace or space platforms.

• Capacity to meet aggressive prototyping timelines.

Companies offering modular, commercially producible systems that leverage dual-use technology trends have a competitive edge

Are there any restrictions I should know about?

Must comply with 10 USC 4022 OT authority requirements for award eligibility.

• All submissions must certify no Controlled Unclassified Information (CUI) unless expressly allowed.

• Awarded agreements will include compliance language for Section 889 of the 2019 NDAA.

How long will it take me to prepare an application?

Most DIU Solution Briefs are 5 pages or ~15 slides and should specifically address the challenge and key solution attributes. Preparation time depends on your level of readiness but planning 2–6 weeks to align technical, programmatic, and compliance content is reasonable.

How can BW&CO help?

BW&CO can support you to:

• Translate DIU requirements into a winning Solution Brief that aligns with your tech and DoD’s need.

• Craft compelling narrative for detection, tracking, and fire-control relevance.

• Map technical milestones and prototyping costs for rapid award.

• Prepare compliant attachments (e.g., SAM/SAM.gov, CAGE, IP/Section 889 compliance).

How much would BW&CO Charge?

Fractional support is $300 per hour.

For startups, we offer a discounted rate of $250 per hour to make top-tier consulting more accessible while maintaining the same level of strategic guidance and proposal quality.

Additional Resources

Review the solicitation here.

DIU - Deorbit as a Service

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

Act now — Responses due February 13, 2026 at 23:59:59 US/Eastern for Deorbit as a Service, a high-priority Defense Innovation Unit (DIU) Commercial Solutions Opening (CSO) to solve a strategic orbital debris and space sustainability challenge. This solicitation funds scalable autonomous technologies that can deorbit unprepared satellites safely and reliably, reducing orbital congestion and enabling future space operations. This is a rare fast-paced opportunity to partner with the U.S. Department of Defense (DoD) using flexible Other Transaction Authority with potential follow-on production contracts without further competition — massive market potential.

How much funding would I receive?

The BAA does not specify a fixed award size; funding will depend on DIU’s evaluation and negotiation of selected prototypes under the CSO. Awards are issued as Prototype Other Transaction (OT) agreements and can scale into larger production contracts if prototypes meet performance milestones.

What could I use the funding for?

This funding is intended to support:

• Development of scalable deorbit systems (hardware + software).

• Rapid prototyping and integrated testing within 18–24 months.

• Safety & CONOPS development for rendezvous, proximity ops, and deorbit.

• Risk-mitigation engineering for non-cooperative satellite interaction.

• Commercial-ready production and launch planning.

Are there any additional benefits I would receive?

Yes — strategic advantages include:

• Fast DIU prototype contracting using Other Transaction Authority.

• Potential for follow-on production contracts without a new competitive process upon successful prototype completion.

• Direct DoD engagement and visibility.

• Entry into the defense space ecosystem with future technology transition opportunities.

What is the timeline to apply and when would I receive funding?

• Application Deadline: February 13, 2026 at 23:59:59 US/Eastern — no extensions guaranteed.

• Phase 1 Evaluation: Review of Solution Briefs.

• Phase 2 (if selected): Pitch & potential invitation to full proposal.

• Prototype Award: Typically within weeks/months after Phase 2 selection.

• Prototype Delivery: 18–24 months expected.

Where does this funding come from?

Funding is provided through the Defense Innovation Unit (DIU) under the DoD’s Commercial Solutions Opening (CSO) process, using Other Transaction Authority (OTA) that enables rapid non-FAR contracting to prototype commercial solutions relevant to national security.

Who is eligible to apply?

U.S. and international companies can submit.

1. Must satisfy 10 USC §4022(d) conditions for OT eligibility: significant nontraditional contribution or required small business participation, or non-government cost share.

2. Companies without a CAGE code must register in SAM.gov early.

What companies and projects are likely to win?

Solutions that demonstrate:

• System-level capability for autonomous deorbit operations.

• Proven hardware + software maturity suitable for prototyping/launch.

• Clear safety and fault-management plans.

• Commercial scalability and cost-efficient operations.

• Collaborative readiness with government and commercial partners.

Are there any restrictions I should know about?

Your Solution Brief must be PDF, ≤10MB with recommended ~5 pages or ~15 slides.

1. Data must not exceed Controlled Unclassified Information unless certified.

2. Must comply with Section 889 of the FY2019 NDAA (restricting certain telecom equipment).

How long will it take me to prepare an application?

Preparation time varies by team readiness:

• Fast track: 1–2 weeks with existing conceptual materials.

• Full brief + detailed CONOPS: 3–6+ weeks if ramping from scratch.

Given the February 13 deadline, start now — opportunities like this are rare and high impact.

How can BW&CO help?

BW&CO can:

• Convert your technology narrative into a winning Solution Brief tailored for DIU evaluation criteria.

• Advise on risk mitigation, CONOPS articulation, and transition planning to increase award likelihood.

• Support teaming strategies with complementary partners to bolster competitiveness.

How much would BW&CO Charge?

Fractional support is $300 per hour.

For startups, we offer a discounted rate of $250 per hour to make top-tier consulting more accessible while maintaining the same level of strategic guidance and proposal quality.

Additional Resources

Review the solicitation here.

Installation Energy & Water - Environmental Security Technology Certification Program (ESTCP)

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

The Environmental Security Technology Certification Program (ESTCP) is soliciting pre-proposals for FY 2027 to fund formal demonstrations of innovative Installation Energy & Water technologies. ESTCP supports mature technologies that improve energy resilience, water resilience, cybersecurity, and building performance at DoD installations through real-world demonstrations conducted at DoD facilities. Pre-proposals are due March 26, 2026 at 2:00 p.m. ET.

How much funding would I receive?

ESTCP awards typically support multi-year demonstration projects funded through cost-type or firm fixed-price contracts. While individual award sizes are not specified in the solicitation, projects commonly range from hundreds of thousands to several million dollars, depending on scope, duration, and demonstration scale.

What could I use the funding for?

Funding may be used to demonstrate and validate innovative technologies in one of the following ESTCP FY 2027 Installation Energy & Water Topic Areas:

Improve Energy Resilience with Long-Duration Energy Storage
This topic area seeks demonstrations of Long Duration Energy Storage (LDES) technologies integrated into military microgrids to meet the DoD’s requirement to power critical loads for 14 days during a grid outage. Technologies of interest include electrochemical, chemical, thermal, subsurface, and other LDES approaches, evaluated through Hardware-in-the-Loop (HIL) testing. The focus is on reducing or eliminating reliance on diesel fuel while improving lifecycle cost-effectiveness, resilience, and cybersecurity of installation microgrids.
Read more here.

Improving the Cyber Resilience of DoW Installation Energy Systems
This topic focuses on closing critical cybersecurity gaps in Facility-Related Control Systems (FRCS) that support energy and water infrastructure. ESTCP is seeking demonstrations of novel solutions that improve secure connectivity, threat detection, and cyber defense at machine speed, including alternatives to fiber connectivity, high-fidelity honeypots, and AI-driven defensive cyber agents. The goal is to reduce the risk of cyber-physical disruption to mission-critical installation systems without requiring major infrastructure modifications.
Read more here.

Improving the Energy Resilience of DoW Installations
This topic area solicits technologies that enhance the ability of military installations to continue mission-critical operations during energy disruptions. Solutions may include hardware, software, planning tools, infrastructure hardening, or integrated energy-water-control approaches, but exclude LDES-only solutions, which must submit under the LDES topic. Technologies should reduce dependence on imported energy, address regional challenges (e.g., arctic, remote, or arid locations), and demonstrate scalability across multiple installations.
Read more here.

Solutions to Improve Energy Efficiency and Performance of DoW Buildings
This topic seeks demonstrations of innovative retrofit-ready technologies that reduce energy use intensity, lower maintenance burden, improve occupant health, and decrease lifecycle costs in DoD buildings. Technologies of interest include HVAC, building envelope systems, lighting, water heating, waste heat recovery, and integrated control solutions. ESTCP prioritizes solutions that work with existing infrastructure, deliver measurable energy savings, and have a clear pathway to adoption through ESCOs, ESPCs, or utility programs.
Read more here.

Water Resilience on DoW Installations
This topic area focuses on technologies and methodologies that improve the reliability, security, and efficiency of water systems supporting military missions. Areas of interest include potable water reduction, water storage (minimum 8,000 gallons), desalination improvements, leak detection, corrosion-resistant materials, building-scale water reuse, and advanced water monitoring. Solutions should reduce operational burden, address water-stressed regions, and support long-term resilience of aging installation water infrastructure.
Read more here.

Are there any additional benefits I would receive?

Beyond the direct funding award, ESTCP provides significant strategic advantages:

• DoD Validation and Credibility: ESTCP selection signals that your technology meets high-priority DoD installation needs and has passed rigorous technical review.

• Accelerated Adoption Pathways: Demonstrations are explicitly designed to support transition, regulatory acceptance, and scaling across multiple DoD installations.

• Non-Dilutive Growth: ESTCP funding allows companies to mature and validate technology without giving up equity, strengthening long-term enterprise value.

• Visibility with Defense Stakeholders: Successful projects are published, presented, and shared across DoD, regulatory, and industry communities—raising profile and credibility.

What is the timeline to apply and when would I receive funding?

• Pre-Proposals Due: March 26, 2026 (2:00 p.m. ET)

• Full Proposal Invitations: May 2026

• Full Proposals Due: July 2026

• Technical Committee Briefings: August 2026

• Project Selection: September 2026

• Anticipated Contract Awards: Q3 FY 2027.

Where does this funding come from?

Funding is provided by the Environmental Security Technology Certification Program (ESTCP) under the Office of the Deputy Assistant Secretary of Defense (Energy Resilience & Optimization) within the U.S. Department of Defense.

Who is eligible to apply?

Eligibility depends on organization type:

• Private industry and universities: Apply under the FY27 ESTCP Broad Agency Announcement (BAA)

• DoD organizations: Apply under the FY27 DoD Call for Proposals

• Other Federal agencies: Apply under the FY27 Federal Call for Proposals

All proposers must submit a pre-proposal and respond to an eligible Topic Area.

What companies and projects are likely to win?

Successful proposals typically:

• Address a clearly defined, enterprise-wide DoD installation need

• Demonstrate technologies at TRL or ARL 5–7

• Provide strong cost, performance, and risk-reduction benefits

• Include a clear DoD end user and transition pathway

• Are scalable across multiple installations and Services

Are there any restrictions I should know about?

Projects will not be considered responsive if they:

• Are already broadly deployed across the DoD enterprise

• Require access to large volumes of high-quality DoD data

• Solve a problem unique to a single installation

• Represent basic research or early-stage exploratory development

How long will it take me to prepare an application?

For first time applicants, pre-proposals will likely take 35 to 50 hours with assistance.

How can BW&CO help?

Our team specializes in complex federal R&D proposals and can:

• Triple your likelihood of success through proven strategy and insider-aligned proposal development

• Reduce your time spent on the proposal by 50–80%, letting your team focus on technology and operations

• Ensure you are targeting the best opportunity for your project and positioning your company for long-term growth under Federal & State R&D Initiatives.

How much would BW&CO Charge?

Fractional support is $300 per hour.

For startups, we offer a discounted rate of $250 per hour to make top-tier consulting more accessible while maintaining the same level of strategic guidance and proposal quality.

Additional Resources

Review the solicitation here.

ARPA-H - BIOGAMI: Biomolecular Grammar for Protein Aggregation Modulation and Intervention

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

ARPA-H’s BIOGAMI program is funding teams to predict, detect, and control protein misfolding before disease begins. The program targets intrinsically disordered proteins (IDPs) and regions (IDRs), which are implicated in neurodegeneration, cancer, diabetes, and other chronic diseases and are largely considered “undruggable.”

Solution Summary Due: March 4, 2026 (12:00 PM ET)

Funding & Structure

1. Awards: Multiple OT awards anticipated

2. Program Length: Up to 48 months

3. Phases:

   • Phase 1 (0–24 months): Model IDR behavior and demonstrate early modulation and sensing

   • Phase 2 (25–48 months): Translate to preventative therapeutics and early detection tools

4. Down-selection occurs after Phase 1 based on quantitative technical metrics.

What ARPA-H Is Trying to Build

BIOGAMI aims to create a generalizable, reusable platform that can:

• Predict IDR structure, dynamics, aggregation, and interactions from sequence

• Modulate protein folding to prevent or reverse aggregation

• Identify early indicators of misfolding—before symptoms appear

• Enable new therapeutic classes for currently undruggable targets

The program emphasizes root-cause intervention, not symptomatic treatment.

Technical Scope (Both Required)

Technical Area 1 (TA1): Molecular Grammar of IDRs

TA1 teams must establish foundational models that explain how IDR sequences and environments drive protein behavior.

Key requirements include:

• Integrated AI/ML + experimental approaches

• High-throughput in vitro, cell-based, and in vivo systems

• Prediction of structure, aggregation, condensate formation, and interactomes

• Validation across diverse sequences, conditions, and post-translational modifications

• Open-source sharing of TA1 models and datasets

By Phase 2, models must predict and validate IDR properties within 60 days of receiving a sequence.

Technical Area 2 (TA2): Modulate IDPs to Detect and Control Folding

TA2 focuses on therapeutic and diagnostic translation.

Teams must:

• Prevent or reverse aggregation and restore protein function

• Develop early, clinically translatable indicators of misfolding

• Target two diseases:

  • One rare disease (<1 in 100,000)

  • One non-rare disease
    (across neurodegenerative and non-neurodegenerative categories)

By Phase 2, teams must:

• Demonstrate in vivo efficacy

• Preserve or restore >90% of critical protein function

• Validate ≥1 novel biomarker and prepare for FDA Biomarker Qualification engagement

Eligible Applicants

• Startups and large companies

• Universities and nonprofits

• Multi-party teams required (not prime/sub)

• Not eligible:

• FFRDCs and government entities as performers

• Entities from covered foreign countries or foreign entities of concern

• Work is prioritized to be performed in the United States.

Evaluation Criteria (In Order)

Scientific and technical merit

1. Team capability and experience

2. Relevance to ARPA-H mission and health impact

3. Cost realism and value

Commercialization Expectations

1. 5-year and 10-year commercialization plans required

2. Translation Advisory Board required

3. Active or planned commercial partnerships strongly encouraged

4. TA2 outputs expected to be positioned for pre-clinical development

How can BW&CO help?

BW&CO helps biotech and deep-tech teams quickly determine whether BIOGAMI is the right opportunity and, if so, how to pursue it with a credible, ARPA-H–ready strategy by translating dense solicitation language into clear founder-level guidance, pressure-testing technical and team fit against TA1/TA2 requirements and metrics, shaping a compelling program narrative that aligns AI, biology, and validation, designing compliant multi-party teaming structures, aligning commercialization and open-source expectations, and proactively flagging proposal risks—so teams can move confidently toward a competitive submission or make an informed decision to walk away.

How much would BW&CO Charge?

With a flat rate of $4000, you’d work with our grant writing team to put the solution summary together and submit before the March 4th deadline.

Additional Resources

Review the solicitation here.